Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28941145 | 0.86 | XDH (0.43) | XDHMAPTSMN1; SMN2 | |
| SCHEMBL21395423 | 0.83 | XDH (0.31) | XDHF2RL3 | |
| SCHEMBL19783390 | 0.78 | ALDH1A1 (0.34) | XDHMAPTSMN1; SMN2 | |
| SCHEMBL19776433 | 0.75 | ALDH1A1 (0.45) | MAPTSMN1; SMN2 | |
| SCHEMBL19776431 | 0.74 | F2RL3 (0.44) | F2RL3 | |
| SCHEMBL9089178 | 0.73 | NQO2 (0.38) | F2RL3 | |
| SCHEMBL29481835 | 0.73 | CCR1 (0.36) | F2RL3 | |
| SCHEMBL19776270 | 0.72 | F2RL3 (0.38) | MAPTF2RL3 | |
| SCHEMBL21379355 | 0.70 | KDM4E (0.43) | XDHSMN1; SMN2F2RL3 | |
| SCHEMBL30189831 | 0.70 | KDM4E (0.43) | XDHSMN1; SMN2F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | XDH 370/4885MAPT 1155/4885SMN1; SMN2 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.